# Eupraxia Pharmaceuticals Inc.: Form 40-F for the period ended Dec 31, 2023

- Company: [Eupraxia Pharmaceuticals Inc.](/companies/eprx.md) (CIK 1581178)
- Form: 40-F
- Filed: 2024-04-01
- Accepted by EDGAR: Apr 1, 2024, 21:11 ET
- Period: 2023-12-31
- Accession: 0001193125-24-083584
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1581178/000119312524083584/d800041d40f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1581178/000119312524083584/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-31 | $0 | us-gaap:Revenues |
| Research and development | 12 months, 2023-01-01 to 2023-12-31 | $20.6m | us-gaap:ResearchAndDevelopmentExpense |
| Interest expense | 12 months, 2023-01-01 to 2023-12-31 | $1.2m | us-gaap:InterestExpense |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $36.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | −$28.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | −$1.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | −$1.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-31 | 24,146,623 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | −$20.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2023-12-31 | $19.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $19.8m | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $20.3m | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $19.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-31 | $19.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-12-31 | $2.2m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2023-12-31 | 27,282,165 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1581178/000119312524083584/d800041d40f.htm

Filed Apr 1, 2024.
Source: SEC EDGAR, the filing index for accession 0001193125-24-083584. Last ingested by Listed: Oct 24, 2026, 15:14 ET. No prices; not investment advice.